Suppr超能文献

坦索罗辛在远端输尿管结石药物排石治疗中的疗效与安全性:一项安慰剂对照试验的系统评价和荟萃分析

Efficacy and Safety of Tamsulosin in the Medical Expulsion Therapy for Distal Ureteral Calculi: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials.

作者信息

Tao Rong-Zhen, Qin Zhi-Qiang, Liu Fa-de, Lv Jian-Lin

机构信息

Department of Urology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.

Department of Urology, Nanjing First Hospital, Nanjing, Jiangsu, China.

出版信息

Urol J. 2019 Jun 17;16(3):224-231. doi: 10.22037/uj.v0i0.4758.

Abstract

PURPOSE

Tamsulosin, a medical expulsive therapy (MET), was always recommended for patients with distal ure-teral calculi less than 10 mm. The aim of the systematic review was to assess the efficacy and safety of tamsulosin in MET compared with placebo.

MATERIALS AND METHODS

A comprehensive search was conducted in the databases PubMed, EMBASE and Web of Science for relevant articles, covering all the literatures published until April 2018. All placebo controlled trails were identified in which patients were randomized to receive either tamsulosin or placebo for distal ureteral calculi.

RESULTS

A total of seven placebo controlled studies including 4135 patients met the inclusion criteria and were involved in the review. We found that tamsulosin was associated with a significantly higher expulsion rate (ESR) [odds ratio (OR) = 1.10, 95% confidence interval (CI) = 1.00-1.21] than placebo in patients with distal ureteral stones less than 7 mm. The ESR ranged from 67.0%-90.7%. But the significant difference was better seen in pa-tients with distal ureteral stones less than 10 mm (OR = 1.11, 95% CI = 1.01-1.21). Even though tamsulosin has a higher incidence of retrograde ejaculation than placebo, no significant difference was observed in the incidence of other adverse events.

CONCLUSION

The results of the current meta-analysis indicated that tamsulosin was superior to placebo in its effi-cacy for distal ureteral stones though retrograde ejaculation was worse with tamsulosin use. It should be a safe and effective medical expulsive therapy choice for distal ureteral stones when stone sizes are less than 10 mm.

摘要

目的

坦索罗辛作为一种药物排石疗法(MET),一直被推荐用于治疗直径小于10mm的远端输尿管结石患者。本系统评价的目的是评估坦索罗辛在MET中与安慰剂相比的疗效和安全性。

材料与方法

在PubMed、EMBASE和Web of Science数据库中进行全面检索以查找相关文章,涵盖截至2018年4月发表的所有文献。识别出所有安慰剂对照试验,其中患者被随机分配接受坦索罗辛或安慰剂治疗远端输尿管结石。

结果

共有7项包括4135例患者的安慰剂对照研究符合纳入标准并纳入本评价。我们发现,在直径小于7mm的远端输尿管结石患者中,坦索罗辛的排石率(ESR)显著高于安慰剂[优势比(OR)=1.10,95%置信区间(CI)=1.00 - 1.21]。ESR范围为67.0% - 90.7%。但在直径小于10mm的远端输尿管结石患者中差异更显著(OR = 1.11,95%CI = 1.01 - 1.21)。尽管坦索罗辛导致逆行射精的发生率高于安慰剂,但在其他不良事件的发生率上未观察到显著差异。

结论

当前荟萃分析的结果表明,坦索罗辛在治疗远端输尿管结石的疗效上优于安慰剂,尽管使用坦索罗辛会使逆行射精情况更严重。对于直径小于10mm的远端输尿管结石,它应是一种安全有效的药物排石疗法选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验